Pacific Biosciences of California, Inc.

PACB

Find Out if You Qualify for a Financial Reward by filling out the form below.

Pacific Biosciences of California, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026. PACB attributed it to “an increasing number of customers delay instrument purchases and we experienced some unexpected softness in consumable shipments.” Analysts reacting to the preannounced results were surprised by the significance of the miss and resulting guide down, noting it was “alarming” and “far worse than we expected.”

Following this news, PACB’s stock price fell by $1.44 per share to close at $1.40 per share.

Active Cases

Ticker Symbol Company Name Join Deadline Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join
MRK Merck & Co., Inc. April 14, 2025 Join
VG Venture Global, Inc. April 18, 2025 Join
STZ Constellation Brands, Inc. April 21, 2025 Join
SWKS Skyworks Solutions, Inc. May 05, 2025 Join